Description: Dimerix Bioscience Ltd, formerly Dimerix Bioscience Pty Ltd, is engaged in developing and commercializing drug therapies and drug discovery tools. The Company’s business activity focuses on the clinical development of the Company’s therapeutic product (DMX200), which is targeted at treatind patients with chronic kidney disease; the development of other therapeutic oppurtunities generated from the use of its cell-based drug discovery assay technology (know as Receptor-HIT), and growing its assay business through the use of Receptor-HIT to assist third parties in their own drug discovery and development processes through contract research. DMX200 is a therapeutic approach to treating chronic kidney disease. It comprises two drugs: irbesartan and propagermanium.
Home Page: dimerix.com
DXB Technical Analysis
425 Smith Street
Fitzroy,
VIC
3065
Australia
Phone:
1300 813 321
Officers
| Name | Title |
|---|---|
| Dr. Nina Webster B.Sc., M.B.A., M.IP.Law, MBA, Ph.D. | CEO, MD & Director |
| Dr. Ashish Soman M.B.A., M.D., MBBS | Chief Medical Officer |
| Mr. Hamish George B.Com., C.A. | CFO & Company Sec. |
| Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D. | Chief Scientific Advisor |
| Ms. Elizabeth McCall B.Com(Hons), B.Juris, BJURIS, GAICD, L.L.B., LLB. | Bus. Devel. Officer |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.6709 |
| Price-to-Sales TTM: | 8.1883 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |